Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2015) 37 EP454 | DOI: 10.1530/endoabs.37.EP454

ECE2015 Eposter Presentations Diabetes (complications & therapy) (143 abstracts)

Lixisenatide improves glycaemic control and body composition in uncontrolled type 2 diabetic patients treated with insulin

Florentino Carral , Carmen Ayala , Antonia Piñero , Ana Isabel Jiménez , Coral Exposito & Concepción García


Endocrinology Department, Puerto Real University Hospital, Puerto Real, Cádiz, Spain.


Objective: Evaluate the efficacy and safety of adding lixisenatide to uncontrolled type 2 diabetic (T2DM) patients treated with insulin.

Methods: A prospective uncontrolled study was designed. Primary endpoints (measured at 3 and 6 months) were change in HbA1c, weight, and insulin doses. Variables analysed were: HbA1c level, insulin and other hypoglycaemic agents doses, capillary glucose tests, number and type of hypoglycaemias, side effects and body composition analysis (Tanita SC-330).

Results: Data from 42 T2DM patients (55% women; mean age: 57.7±7.4 years; and T2DM duration: 13.5±8.7 years) treated with insulin were analysed. A significant decrease in HbA1c levels (7.6±0.8% vs 7.8±1.1% vs 9.1±1.6%; P<0.001) and weight (95.2±14.8 kg vs 95.8±14.4 kg vs 98.5±13.9 kg) was observed at 3 and 6 months compared to baseline and % of fat mass had also reduced at 6 months (33.9±7.6% vs 38.8±8.1%; P: 0.01). Total insulin doses decreased from baseline (61.2±37.3 UI/day) to 3 (52.5±34.8 UI/day; P: 0.02) and 6 months (49.4±30.5 UI/day; P: 0.021). Low incidence of no serious hypoglycaemias (1.0±1.7 mean episodes/month) was referred. Six patients (14.2%) discontinued lixisenatide treatment due to side effects (four patients for nausea or vomiting, one patients for hypertransaminasemia, and one patient for uncontrolled hyperglycaemia). Three patients (7.1%) were lost to follow-up for unknown reasons.

Conclusions: In our clinical experience, lixisenatide contributes to improving glycaemic control as facilitates weight loss and insulin doses reduction in T2DM patients uncontrolled with insulin.

Article tools

My recent searches

No recent searches.